Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study

Background: To compare adverse event (AE) profiles between patients with prostate cancer receiving triplet therapy (docetaxel, androgen receptor signaling inhibitors [ARSIs], and androgen deprivation therapy [ADT]) and those receiving docetaxel-based therapy (docetaxel and ADT). Additionally, we sou...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Fumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, Hidetsugu Takahashi, Masaki Hashimoto, Shuhei Hara, Wataru Fukuokaya, Yu Imai, Kosuke Iwatani, Taro Igarashi, Mahito Atsuta, Kojiro Tashiro, Masaya Murakami, Shunsuke Tsuzuki, Brendan A. Yanada, Toshihiro Yamamoto, Kenichi Hata, Hiroki Yamada, Jun Miki, Takahiro Kimura
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-03-01
Serie:	Prostate International
Soggetti:	Adverse event Docetaxel mCSPC Neutropenia Triplet therapy
Accesso online:	http://www.sciencedirect.com/science/article/pii/S2287888224000850
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!